Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

Kister, Ilya; Spelman, Tim; Patti, Francesco; Duquette, Pierre; Trojano, Maria; Izquierdo, Guillermo; Lugaresi, Alessandra; Grammond, Pierre; Sola, Patrizia; Ferraro, Diana; Grand'Maison, Francois; Alroughani, Raed; TERZİ, MURAT; BOZ, CAVİT; Hupperts, Raymond; Lechner-Scott, Jeannette; Kappos, Ludwig; Pucci, Eugenio; Hodgkinson, Suzanne; Solaro, Claudio; Butzkueven, Helmut

doi:10.1016/j.jns.2018.06.001

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

Atıf İçin Kopyala

Kister I., Spelman T., Patti F., Duquette P., Trojano M., Izquierdo G., ...Daha Fazla

JOURNAL OF THE NEUROLOGICAL SCIENCES, cilt.391, ss.72-76, 2018 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 391
Basım Tarihi: 2018
Doi Numarası: 10.1016/j.jns.2018.06.001
Dergi Adı: JOURNAL OF THE NEUROLOGICAL SCIENCES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.72-76
Anahtar Kelimeler: Multiple sclerosis, Relapse, Disability, Disease modifying therapy, Observational cohort study, MULTIPLE-SCLEROSIS, FINGOLIMOD TREATMENT, NATALIZUMAB, WITHDRAWAL, CESSATION, COHORT
Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Background: Discontinuation of disease-modifying therapies (DMTs) for MS is common. MSBase, a large global observational registry, affords a unique opportunity to investigate predictors of 'post-DMT' relapses and confirmed disability progression (CDP) in a diverse group of patients exposed to different DMTs.